According to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) and European Society for Medical Oncology guidelines, assessment of cytogenetic abnormalities and testing for TP53 mutations and IGHV status should be applied in routine clinical practice to guide the treatment selection alongside the patient's clinical stage and symptoms [4, 21]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.